Side by side: size, value over time, results, valuation, margins, growth, debt and shareholder returns, and any of thirty figures charted over the years (up to 6).
Open these as a peer group: up to 12 companies with suggested peers, each company's rank in the group and percentile in its sector and country, saved for you or your team.
From Jan 2020: how each company's value moved, whatever its size.
US$ billions, as reported in each year's annual results.
Revenue of the fiscal year. US dollars at each year's exchange rate.
| Measure | Deva Holding A.S.✕ DEVA.IS | Evolus, Inc.✕ EOLS · #12,552 in the world |
|---|---|---|
| Profile | ||
| Country | 🇹🇷 Turkey | 🇺🇸 USA |
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceutical | Pharmaceutical |
| Founded | — | 2012 |
| Size | ||
| Market cap | ||
The largest companies, each against its nearest peers in value from the same industry.
| Fiscal year | Deva Holding A.S. | Evolus, Inc. |
|---|---|---|
| 2025 | — | $297 MSEC |
| 2024 | — | $266 MSEC |
| 2023 | — | $202 MSEC |
| 2022 | — | $149 MSEC |
| 2021 | — | $100 MSEC |
| 2020 | — | $57 MSEC |
| 2019 | — | $35 MSEC |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports; Ed. = the company's report (editors); WD = Wikidata, citing the annual report; Cap = value.today market caps. Hover a figure for its period.
| $526 M* |
| $501 M |
| Revenue | — | $297 M |
|---|
| Net income | — | $-52 M |
|---|
| Employees | — | 334 |
|---|
| Valuation | ||
|---|---|---|
| Price to sales | — | 1.5× |
| Free cash flow yield | — | -9.1% |
| Profitability | ||
|---|---|---|
| Gross margin | — | 66.3% |
| Operating margin | — | -11.0% |
| Net margin | — | -17.4% |
| Growth | ||
|---|---|---|
| Revenue growth | — | 11.6% |
| Revenue growth, 3 years a year | — | 26.0% |
| Cash | ||
|---|---|---|
| Free cash flow margin | — | -15.4% |
| Strength scores | ||
|---|---|---|
| Piotroski F-score | — | 2 of 9 |
| Altman Z-score zone | — | distress |
|---|
| Data as of | Market cap Jan 2024 | Market cap Oct 2026; ratios FY2025 |
|---|
Market caps from exchange data or SEC filings on the date shown (* last known value, no current one); revenue and net income from the latest annual results; ratios worked out from each company's own statements for the fiscal year shown. ▲ marks the best of these companies where higher or lower is better; size and valuation multiples are marked for no one. Definitions: methodology.